The molecular immunology of mucositis: Implications for evidence-based research in alternative and complementary palliative treatments

Evidence-based Complementary and Alternative Medicine

Volumn 2, Issue 4, 2005, Pages 489-494

  Chiappelli, Francesco ^a  

^a UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

Evidence based research; GM CSF; Molecular immunology; Mucositis

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; BENZYDAMINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; JANUS KINASE; LIDOCAINE; PREDNISONE; PROTEIN KINASE B; RETINOL; STAT PROTEIN; SUCRALFATE; SUPPRESSOR OF CYTOKINE SIGNALING; TRICLOSAN;

ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL DEATH; CIGARETTE SMOKING; CYTOTOXICITY; DIGESTIVE SYSTEM INFLAMMATION; DISEASE SEVERITY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL MUCOSA; HEALTH CARE COST; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; MOUTH FLORA; MOUTH HYGIENE; MUCOSA INFLAMMATION; PAIN; PHARYNX DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMATITIS;

EID: 28644451400     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/neh129     Document Type: Review

References (39)

1. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-51.
2. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-46.
3. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology 2003;17:1767-79, discussion 1779-82, 1791-2.
4. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-32; discussion 35-6.
5. Chiappelli F. Immunity. In: Fink G (ed). Encyclopaedia of Stress. Academic Press, New York, 2005 (in press).
6. Alvarado Y, Bellm LA, Giles FJ. Oral mucositis: time for more studies. Hematology 2002;7:281-9.
7. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 2003;18:853-74.
8. Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches?. Cancer Nurs 2004;27:183-205.
9. Dodd MJ, Miaskowski C, Shiba GH, Dibble SL, Greenspan D, MacPhail L, et al. Risk factors for chemotherapy-induced oral mucositis: dental appliances, oral hygiene, previous oral lesions, and history of smoking. Cancer Invest 1999;17:278-8.
10. Bolwell BJ, Kalaycio M, Sobecks R, Andresen S, Kuczkowski E, Bernhard L, et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002;30:587-91.
11. Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients receiving treatment. Cochrane Database Syst Rev 2003;3:CD000978.
12. Loprinzi CL, Gastineau DA, Foote RL. Oral complications. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds). Clinical Oncology. New York: Churchill Livingstone, 1995, 741-54.
13. Blocklehurst P, McGuire W. Evidence-based care. Br Med J 2005;330:36-8.
14. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003;25:1057-70.
15. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:949-54.
16. Buchsel PC, Forgey A, Grape FB, Hamann SS. Granulocyte macrophage colony-stimulating factor: current practice and novel approaches. Clin J Oncol Nurs 2002;6:198-205.
17. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004;28:509-54.
18. Xu J, Lucas R, Wendel A. The potential of GM-CSF to improve resistance against infections in organ transplantation. Trends Pharmacol Sci 2004;25:254-8.
19. van der Pouw Kraan TC, Kasperkovitz PV, Verbeet N, Verweij CL. Genomics in the immune system. Clin Immunol 2004;111:175-85.
20. Tewari M, Hu PJ, Ahn JS, Ayivi-Guedehoussou N, Vidalain PO, Li S, et al. Systematic interactome mapping and genetic perturbation analysis of a C. elegans TGF-beta signaling network. Mol Cell 2004;13:469-82.
21. Jackson SH, Yu CR, Mahdi RM, Ebong S, Egwuagu CE. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol 2004;172:2307-15.
22. Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 2004;4:889-99.
23. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004;4:408-14.
24. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005;10:975-84.
25. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004;23:2617-29.
26. Rochford R, Riggs JE, Clavo A, Ernst DN, Hobbs MV. Differential effects of CD28 costimulation upon cytokine production by CD4+ and CD8+ T cells. Immunobiology 2004;209:513-22.
27. Kubo T, Hatton RD, Oliver J, Liu X, Elson CO, Weaver CT. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 2004;173:7249-58.
28. Okuda K, Foster R, Griffin JD. Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann NY Acad Sci 1999;872:305-12; discussion 312-3.
29. Franzen R, Bouhy D, Schoenen J. Nervous system injury: focus on the inflammatory cytokine 'granulocyte-macrophage colony stimulating factor'. Neurosci Lett 2004;361:76-8.
30. Czura CJ, Friedman SG, Tracey KJ. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. J Endotoxin Res 2003;9:409-13.
31. Rossi EL. Stress-induced alternative gene splicing in mind-body medicine. Adv Mind Body Med 2004;20:12-9.
32. Romeo H, Tio DL, Rahman SU, Chiappelli F, Taylor AN. The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: Relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 2001;115:91-100.
33. Fischbein NJ, Dillon WP. Imaging of otolaryngologic manifestations of HIV infection. Neuroimaging Clin N Am 1997;7:375-99.
34. Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs 2004;6:147-59.
35. Lichtman SM. Physiological aspects of aging. Implications for the treatment of cancer. Drugs Aging 1995;7:212-25.
36. Syrjala KL, Donaldson GW, Davis MW, Kippes ME, Carr JE. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain 1995;63:189-98.
37. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 2000;20:374-87.
38. Matsuoka H, Mizushima Y, Kawano M, Tachibana N, Sawada Y, Kato S, et al. Clinical availability of the herbal medicine, Syousaikotou, as a gargling agent for prevention and treatment of chemotherapy-induced stomatitis. Gan To Kagaku Ryoho 2004;31:2017-20.
39. Yuki F, Kawaguchi T, Hazemoto K, Asou N. Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukemia. Gan To Kagaku Ryoho 2003;30:1303-7.